Coronary Obstruction From TAVR in Native Aortic Stenosis: Development and Validation of Multivariate Prediction Model.

Autor:	Khan JM; Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC, USA; Cardiovascular Branch, Division of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA., Kamioka N; Structural Heart and Valve Center, Emory University Hospital, Atlanta, Georgia, USA; Department of Cardiology, Tokai University School of Medicine, Isehara, Japan., Lisko JC; Structural Heart and Valve Center, Emory University Hospital, Atlanta, Georgia, USA., Perdoncin E; Structural Heart and Valve Center, Emory University Hospital, Atlanta, Georgia, USA., Zhang C; Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC, USA., Maini A; Georgetown University School of Medicine, Washington, DC, USA., Chen M; Department of Cardiology, West China School of Medicine, West China Hospital, Sichuan University, China., Li Y; Department of Cardiology, West China School of Medicine, West China Hospital, Sichuan University, China., Ludwig S; Department of Cardiology, University Heart and Vascular Center Hamburg, Hamburg, Germany; Cardiovascular Research Foundation, New York, New York, USA., Westermann D; Department of Cardiology and Angiology I, University Heart Center Freiburg - Bad Krozingen, Medical Faculty, University of Freiburg, Freiburg, Germany., Amat Santos IJ; Department of Cardiology, Hospital Clínico Universitario de Valladolid, Valladolid, Spain., Kalińczuk Ł; National Institute of Cardiology, Warsaw, Poland., Sinning JM; Heart Center Bonn, University of Bonn, Bonn Germany., Kawaguchi T; Department of Cardiology, Kokura Memorial Hospital, Kitakyushu, Japan., Fuku Y; Department of Cardiology, Kurashiki Central Hospital, Kurashiki, Japan., Cheema AN; Department of Interventional Cardiology, St. Michael's Hospital, Toronto, Ontario, Canada., Félix-Oliveira A; Department of Cardiology, Hospital de Santa Cruz, Centro Hospitalar de Lisboa Ocidental, Lisbon, Portugal; Institute of Pharmacology and Neurosciences, Faculty of Medicine, Lisbon University, Lisbon, Portugal., Yamamoto M; Department of Cardiology, Toyohashi Heart Center/Nagoya Heart Center, Nagoya, Japan., Kagase A; Department of Cardiology, Toyohashi Heart Center/Nagoya Heart Center, Nagoya, Japan., Codner P; Department of Cardiology, Rabin Medical Center, Petah Tikva, Israel., Valle RD; Interventional Cardiology Department, Hospital Universitario Central de Asturias, Oviedo, Spain., Iyer VS; Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York, USA., Kim HS; Division of Cardiology, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea., Lin MS; Division of Cardiology, Department of Internal Medicine, National Taiwan University Hospital, Taipei City, Taiwan., Maini B; Department of Cardiology, Florida Atlantic University, Boca Raton, Florida, USA., Rodriguez R; Structural Heart Program, Main Line Health, Lankenau Medical Center, Wynnewood, Pennsylvania, USA., Montorfano M; Interventional Cardiology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy., Ancona MB; Interventional Cardiology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy., Tada N; Department of Cardiology, Sendai Kosei Hospital, Sendai, Japan., Miyasaka M; Department of Cardiology, Sendai Kosei Hospital, Sendai, Japan., Ahmad H; Department of Cardiology, Westchester Medical Center, Valhalla, New York, USA., Ruggiero NJ; Division of Cardiology, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, USA., Torguson R; Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC, USA., Ben-Dor I; Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC, USA., Shults CC; Department of Cardiac Surgery, MedStar Washington Hospital Center, Washington, DC, USA., Weissman G; Department of Cardiology, MedStar Washington Hospital Center, Washington, DC, USA., Lederman RJ; Cardiovascular Branch, Division of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA., Greenbaum AB; Structural Heart and Valve Center, Emory University Hospital, Atlanta, Georgia, USA., Babaliaros VC; Structural Heart and Valve Center, Emory University Hospital, Atlanta, Georgia, USA., Waksman R; Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC, USA., Rogers T; Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC, USA; Cardiovascular Branch, Division of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA. Electronic address: toby.rogers@medstar.net.
Jazyk:	angličtina
Zdroj:	JACC. Cardiovascular interventions [JACC Cardiovasc Interv] 2023 Feb 27; Vol. 16 (4), pp. 415-425.
DOI:	10.1016/j.jcin.2022.11.018
Abstrakt:	Background: Transcatheter aortic valve replacement (TAVR)-related coronary artery obstruction prediction remains unsatisfactory despite high mortality and novel preventive therapies. Objectives: This study sought to develop a predictive model for TAVR-related coronary obstruction in native aortic stenosis. Methods: Preprocedure computed tomography and fluoroscopy images of patients in whom TAVR caused coronary artery obstruction were collected. Central laboratories made measurements, which were compared with unobstructed patients from a single-center database. A multivariate model was developed and validated against a 1:1 propensity-matched subselection of the unobstructed cohort. Results: Sixty patients with angiographically confirmed coronary obstruction and 1,381 without obstruction were included. In-hospital death was higher in the obstruction cohort (26.7% vs 0.7%; P < 0.001). Annular area and perimeter, coronary height, sinus width, and sinotubular junction height and width were all significantly smaller in the obstructed cohort. Obstruction was most common on the left side (78.3%) and at the level of the coronary artery ostium (92.1%). Coronary artery height and sinus width, but not annulus area, were significant risk factors for obstruction by logistic regression but performed poorly in predicting obstruction. The new multivariate model (coronary obstruction IF cusp height > coronary height, AND virtual valve-to-coronary distance ≤4 mm OR culprit leaflet calcium volume >600 mm 3 ) performed well, with an area under the curve of 0.93 (sensitivity = 0.93, specificity = 0.84) for the left coronary artery and 0.94 (sensitivity = 0.92, specificity = 0.96) for the right. Conclusions: A novel computed tomography-based multivariate prediction model that can be implemented routinely in real-world practice predicted coronary artery obstruction from TAVR in native aortic stenosis. Competing Interests: Funding Support and Author Disclosures This work was supported by a research grant from Medtronic to MedStar Cardiovascular Research Network and MedStar Health. Dr Kamioka has served as a proctor for Edwards Lifesciences. Dr Ludwig has received grant support from the German Heart Foundation; and received travel compensation from Edwards Lifesciences. Dr. Sinning has received speaker honoraria and research grants from Abbott, Abiomed, Medtronic, Boston Scientific, and Edwards Lifesciences; and served as a proctor for Medtronic and Boston Scientific. Dr Fuku has served as a proctor for Edwards Lifesciences and Medtronic. Dr Iyer has served as a proctor for Edwards Lifesciences, Medtronic, and Boston Scientific. Dr Rodriguez has served as a speaker for Medtronic, Abbott, and Edwards Lifesciences. Dr Montorfano has served as a proctor for Edwards Lifesciences, Boston Scientific, and Abbott. Dr Ancona has received consulting fees from Abbott and Abiomed. Dr Ahmad has served as a proctor for Edwards Lifesciences. Dr Ruggiero has served as a proctor for Abbott and Edwards Lifesciences; served as a consultant for Abbott, Edwards Lifesciences, and RegenX-Bio; and received research support from Ancora Heart and Bard. Dr Weissman has served as the director of an academic cardiac computed tomography core lab with institutional contracts with Ancora Heart and LivaNova. Dr Waksman has served on the advisory board for Abbott Vascular, Boston Scientific, Medtronic, Philips IGT, and Pi-Cardia Ltd; has served as a consultant for Abbott Vascular, Biotronik, Boston Scientific, Cordis, Medtronic, Philips IGT, Pi-Cardia Ltd, Swiss Interventional Systems/SIS Medical AG, Transmural Systems Inc, and Venous MedTech; has received institutional grant support from Amgen, Biotronik, Boston Scientific, Chiesi, Medtronic, and Philips IGT; and is an investor in MedAlliance and Transmural Systems Inc. Dr Rogers has served as a proctor and consultant for Boston Scientific, Edwards Lifesciences, and Medtronic; has served on the advisory board for Medtronic; and holds equity interest in Transmural Systems Inc. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. (Copyright © 2023 American College of Cardiology Foundation. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu